ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.
Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Clone 1B4 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects Monocyte differentiation antigen CD14. It targets an epitope within 16 amino acids from the C-terminal region.
KLH conjugated linear peptide corresponding to 16 amino acids from the C-terminal region of human Monocyte differentiation antigen CD14.
Quality Control Testing
Evaluated by Western Blotting in THP-1 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CD14 in THP-1 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CD14 in human liver tissue lysate.
Flow Cytometry Analysis: 0.1 μg from a representative lot detected CD14 in one million THP-1 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CD14 in human tonsil tissue sections.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CD14 in THP-1 cells.
Affinity Binding Assay: A representative lot of this antibody bound CD14 peptide with a KD of 1.0 x 10-12 in an affinity binding assay.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-CD14, clone 1B4 ZooMAb®, Cat. No. ZRB1294, is a recombinant Rabbit monoclonal antibody that specifically targets CD14 and is tested for use in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, and Western Blotting.
Monocyte differentiation antigen CD14 (UniProt: P08571; also known as Myeloid cell-specific leucine-rich glycoprotein, CD14) is encoded by the CD14 gene (Gene ID: 929) in human. CD14 is a GPI-anchor membrane glycoprotein that serves as a co-receptor for several Toll-like receptors. Together with TLR4 and MD-2, it forms the multi-receptor complex that recognizes Lipopolysaccharide (LPS) on the cell membrane. In the presence of LPS, CD14 and TLR4-MD2 are brought into close proximity inside lipid rafts and after translocation into the lipid rafts, TLR4 in the plasma membrane activates the TIRAP-MyD88-dependent pathway that leads to the first wave of NF-B activation. CD14 also acts as a co-receptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides. These clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway. CD14 expression has been reported on cells of both hematopoietic and non-hematopoietic origin. A secreted form of CD14 has also reported that arises from the cleavage of the GPI anchor. CD14 is expressed on macrophages and a strong expression has been reported on the surface of monocytes. Its expression on monocytes is induced by 27-hydroxycholesterol that primes monocytes/macrophages to accelerate LPS-mediated inflammatory reaction. CD14-deficient macrophages display a significantly reduced sensitivity to low concentrations of LPS compared to wild-type cells and CD14 deficient mice do not develop septic shock after exposure to LPS or Gram-negative bacteria. CD14 is synthesized with a signal peptide (aa 1-19) and a propeptide (aa 346-375) that are cleaved off to generate the mature form. The mature form contains 11 leucine-rich repeats (LRR) that are required for responses to smooth LPS. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Zanoni, I., and Granucci, F. (2013). Front. Cell. Infect. Microbiol. 3; 32).
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
30 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.